☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
rocket pharmaceuticals
Rocket Pharmaceuticals Reports the EMA’s Acceptance of MAA for RP-L102 to Treat Fanconi Anemia
April 2, 2024
Rocket Pharmaceuticals Receives the US FDA’s RMAT Designation of RP-A501 for the Treatment of Danon Disease
February 8, 2023
Load more...
Back to Home
Modal title
×
Modal body text goes here.